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Abstract
Plasmodium falciparum causes the most serious complications of malaria and is a public health problem worldwide with
over 2 million deaths each year. The erythrocyte invasion mechanisms by Plasmodium sp. have been well described,
however the physiological aspects involving host components in this process are still poorly understood. Here, we provide
evidence for the role of renin-angiotensin system (RAS) components in reducing erythrocyte invasion by P. falciparum.
Angiotensin II (Ang II) reduced erythrocyte invasion in an enriched schizont culture of P. falciparum in a dose-dependent
manner. Using mass spectroscopy, we showed that Ang II was metabolized by erythrocytes to Ang IV and Ang-(1–7).
Parasite infection decreased Ang-(1–7) and completely abolished Ang IV formation. Similar to Ang II, Ang-(1–7) decreased
the level of infection in an A779 (specific antagonist of Ang-(1–7) receptor, MAS)-sensitive manner. 10
27 M PD123319, an
AT2 receptor antagonist, partially reversed the effects of Ang-(1–7) and Ang II. However, 10
26 M losartan, an antagonist of
the AT1 receptor, had no effect. Gs protein is a crucial player in the Plasmodium falciparum blood cycle and angiotensin
peptides can modulate protein kinase A (PKA) activity; 10
28 M Ang II or 10
28 M Ang-(1–7) inhibited this activity in
erythrocytes by 60% and this effect was reversed by 10
27 M A779. 10
26 M dibutyryl-cAMP increased the level of infection
and 10
27 M PKA inhibitor decreased the level of infection by 30%. These results indicate that the effect of Ang-(1–7) on P.
falciparum blood stage involves a MAS-mediated PKA inhibition. Our results indicate a crucial role for Ang II conversion into
Ang-(1–7) in controlling the erythrocytic cycle of the malaria parasite, adding new functions to peptides initially described
to be involved in the regulation of vascular tonus.
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Introduction
Malaria, one of the most severe parasitic diseases, is caused by
Plasmodium sp. More than 100 species that can infect vertebrates
have been identified in nature and Plasmodium falciparum is the most
lethal among them [1]. Although there have been many efforts to
control the disease, it remains a serious public health problem
worldwide, especially because of multidrug resistance mechanisms
in parasites, development of insecticide resistance in mosquitoes
and the absence of an effective vaccine [2]. This infection affects
mainly the poor population, and morbidity and mortality can be
attributed to the lack of adequate treatment and an early and
accurate diagnosis, constituting an obstacle to efforts toward
economic development [2].
The life cycle of the malaria parasite is extremely complex and is
characterized by an asexual phase, which occurs inside the
vertebrate host, and a sexual phase that develops in the mosquito
vector [3]. The clinical symptoms of the disease usually coincide
with disruption of infected erythrocytes, followed by the release of
merozoites in the circulation, which can infect new red blood cells,
perpetuating the parasite erythrocytic cycle in the asexual phase [3].
The mechanism of erythrocyte invasion by merozoites has been
studied by several groups and it is characterized as a multi-step
process involving host erythrocyte membrane involution and
deformation, leading to invagination and cell swallowing [4,5].
For many years, this mechanism of entry into erythrocytes was
considered to be mediated by parasite factors specially secreted by
apical organelles. Today, it is known that components enriched in
lipid rafts from host erythrocyte membrane are also involved in this
process. Heterotrimeric G protein, specifically the Gs a subunit
(Gas), is present on erythrocyte detergent-resistant membrane rafts
and is recruited to the parasitophorous vacuole [6,7]. Harrison et al.
[8] showed the involvement of erythrocyte G-protein raft-associated
signaling mechanisms in parasite entry. Agonists of adenosine and
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tors that are also recruited to the plasmodial vacuole membrane,
stimulated infection; antagonists reversed these agonist effects.
Murphy et al. [9], by using erythrocyte ghosts, provided final
evidence that erythrocyte Gs signaling is important not only to
invasion but also to parasite intracellular maturation. They
observed that the inhibition of Gs protein prevents the increase in
the production of cAMP induced by isoproterenol and parasite
invasion into erythrocytes [9]. Because cAMP is a well-known
activator of protein kinaseA (PKA) activity, it is possible to postulate
the involvement of this kinase in the erythrocytic cycle of the
malaria parasite. Furthermore, the presence of PKA has been
described in Plasmodium falciparum (PfPKA), which is also involved in
parasite invasion [10]. Thus, based on these observations we can
postulate that peptides that can bind and signal through a member
of the G protein-coupled receptor family (GPCR) could participate
in erythrocyte invasion by Plasmodium sp.
A possible candidate is angiotensin II (Ang II), a peptide that
belongs to the renin-angiotensin system (RAS), which has
confirmed proinflammatory effects and antiplasmodial activity
when injected in the hemolymph of Aedes aegypti contaminated with
Plasmodium gallinaceum by blocking accumulation of sporozoites in
mosquito salivary glands without affecting vector survival [11].
Furthermore, a correlation between mild malaria and patients
with angiotensin I converting enzyme (ACE I/D) and angiotensin
II converting enzyme (ACE2 CRT) has been observed [12]. The
RAS has been shown to be present in different cells of the
hematopoietic system and it seems that Ang II stimulates
erythropoiesis by up-regulating erythropoietin levels and by direct
stimulation of the proliferation of erythroid progenitor cells [13]. It
seems that Ang II receptors have not been characterized in fully
differentiated erythrocytes and direct evidence of their participa-
tion on P. falciparum entry is scarce. In this report, we describe
studies aimed at identifying the molecular mechanisms induced by
Ang II that are involved in the modulation of the P. falciparum
erythrocytic cycle.
Results
Ang II impairs the P. falciparum erythrocytic cycle
To assess the effect of Ang II in the P. falciparum erythrocytic
cycle, increasing concentrations of the peptide (10
212–10
26 M)
were assayed in vitro against a synchronized culture in the schizont
form of the W2 strain of P. falciparum maintaining 5% hematocrit
and 2% parasitemia. Twenty-four hours after treatment, Ang II
was able to reduce parasite invasion in a dose-dependent manner
with the maximum effect observed at 10
28 M, promoting 47% of
inhibition (Fig. 1A,B). The schizont and trophozoite forms
represent less than 10% of total parasites after 24 h. Fig. 1C
shows the correlation between the Ang II-induced inhibition of
parasite invasion and initial inoculum of synchronized culture in
the schizont form of the W2 strain, using increasing parasitemia
from 0.5 to 3%. The inhibitory effect of 10
28 M Ang II was not
changed by different inoculum.
It is known that the effect of Ang II could be lost due to
impairment of the coupled signaling pathways [14]. Therefore, in
a further group of experiments we tested the chronic effect of Ang
II by treating the culture daily with 10
28 M Ang II for 4
consecutive days (2 complete parasite life cycles) with an initial
inoculum of 0.5%. The inhibitory effect of Ang II was maintained
throughout the experiment (Fig. 2A). One question arises from our
data: is the effect of Ang II on parasite growth maintained even in
the absence of a new dose of Ang II? In another group of
experiments, infected erythrocytes (0.5% parasitemia) were pre-
incubated or not with daily doses of Ang II (10
28 M) for 4
consecutive days, as described before. The culture was then split
and maintained for 11 days without Ang II. Parasitemia was then
evaluated. The pre-incubation treatment decreased parasitemia
compared with the control (no pre-incubation with Ang II, Fig. 2B,
bar A), represented by 50% inhibition (Fig. 2B, bar B). The
inhibitory effect of Ang II is maintained even after 11 days in the
absence of a new addition of Ang II (Fig. 2B, bar C).
Figure 1. Angiotensin II reduces erythrocyte invasion by
Plasmodium falciparum. (A) Representative thick blood smears for
parasitemia determination by Diff-Quick staining. Parasite schizont
forms were incubated with a fresh erythrocyte culture at 2%
parasitemia in the absence (left) or presence (right) of 10
28 M Ang II
(n=8). (B) Parasite schizont forms were incubated with a fresh
erythrocyte culture at 2% parasitemia in the absence or presence of
increasing concentrations of Ang II (10
212–10
26 M). Parasite invasion
was determined by the number of intracellular rings after 24 h
incubation as described in the Materials and Methods section (n=8).
(C) The influence of Ang II was evaluated in different inoculum of
parasite schizont forms (from 0.5% to 3%), 24 h after the initial
inoculum, by determining parasite invasion in thick blood smears as
described in the Materials and Methods section (n=6). The results are
expressed as means6SE. *Statistically significant compared with the
control value (P,0.05). Magnification 6100.
doi:10.1371/journal.pone.0017174.g001
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To verify the presence of Ang II receptors on the surface of
erythrocytes, membrane fractions were subjected to immunoblot-
ting analysis. Rat renal cortex homogenate was used as positive
control because it is well known that this preparation has AT1,
AT2 and MAS angiotensin receptors [15–17]. Fig. 3A clearly
shows the presence of the same receptors in erythrocyte plasma
membranes. The molecular weight found for AT1 was a little
higher than that observed in Wistar rat renal cortex homogenate
(43 kDa), the positive control used. In agreement with our results,
AT1 receptor isoforms with molecular weight ranging from 60 to
73 kDa have been observed in the kidneys of the Sprague-Dawley
rat, desert rodent Meriones crassus and human ovarian carcinoma
cells [18,19].
To investigate which receptor was mediating the Ang II effect,
cells were treated with 10
26 M losartan, 10
27 M PD123319 or
10
27 M A779, antagonists of AT1,A T 2 and MAS receptors,
respectively. These antagonists were added 30 min before the
addition of Ang II and maintained during the course of the
reaction with Ang II. The inhibitory effect of Ang II on parasite
invasion was partially abolished when PD123319 was added and
completely abolished in the presence of A779. The addition of
PD123319 or A779 without Ang II did not change the parasite
invasion (Fig. 3B). On the other hand, losartan had the same but
non-additive effect compared with Ang II.
Ang II-derived metabolites mimicked the effect of Ang II
on parasite invasion
So far the scenario indicates that Ang II could modulate parasite
invasion. However, it is well known that Ang II can be
metabolized and, consequently, the metabolites generated could
be active in the modulation of the P. falciparum erythrocytic cycle.
To address this issue, we measured Ang II metabolism using mass
spectroscopy (Fig. 4). Initially, infected and non-infected erythro-
cytes were incubated with 10
25 M Ang II for different times (30–
120 s). The supernatant was collected and analyzed by mass
spectroscopy as described in the Materials and Methods section.
We assessed the level of aminopeptidase-mediated Ang IV and
carboxypeptidase-mediated Ang-(1–7) formation because these
peptides have been reported to have important physiological
effects. The basal levels of Ang II, Ang IV and Ang-(1–7) in the
serum were less than 1% compared with the levels found after the
addition of 10
25 M Ang II. Ang II is metabolized under both
conditions (Fig. 4A). However, its metabolism is significantly lower
Figure 2. Ang II inhibitory effect is maintained for 11 days.
(A) Parasites were incubated with a fresh erythrocyte culture at 0.5%
parasitemia in the absence (#) or presence (N)o f1 0
28 M Ang II, added
daily for 4 consecutive days. Total parasitemia was determined on each
day of the assay as described in the Materials and Methods section
(n=7). (B) The pre-incubation effect of Ang II was determined after
treating the culture without (bar A) or with (bar B) 10
28 M Ang II for 4
days. The culture was then split and maintained for 11 days without
Ang II (bar C). The total parasitemia was determined as described in the
Materials and Methods section (n=5). The results are expressed as
means6SE. *Statistically significant compared with the control value
(P,0.05).
doi:10.1371/journal.pone.0017174.g002
Figure 3. Angiotensin receptors are present in erythrocyte
membranes. (A) Membrane preparations of human erythrocytes (50,
150 or 200 mg total protein, lanes 1, 2 and 3, respectively) underwent
immunoblotting for detection of AT1,A T 2 and MAS receptors. The
microsomal fraction of rat renal cortex was used as positive control
(lane C) (n=3). (B) The Ang II-mediated effect was partially abolished by
AT2 receptor antagonist. Where indicated, cultures were pre-treated
with 10
26 M losartan, 10
27 M PD123319 or 10
27 M A779. Parasite
invasion was determined as the number of intracellular rings after 24 h
incubation as described in the Materials and Methods section (n=6).
The results are expressed as means6SE. Statistically significant
compared with *control and #Ang II values (P,0.05).
doi:10.1371/journal.pone.0017174.g003
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erythrocytes, aminopeptidase-mediated Ang IV and carboxypep-
tidase-mediated Ang-(1–7) formation occurred. However, in
infected erythrocytes, a decrease in the level of Ang-(1–7) and
complete inhibition of the formation of Ang IV were observed,
indicating that the metabolic pathways are under differential
regulation in the presence of the parasite (Fig. 4B,C). Thus, these
results suggest that the effect of Ang II on the erythrocytic parasite
cycle could be mediated by its carboxypeptidase-mediated
metabolic product Ang-(1–7). We then tested whether or not the
effect of Ang II could be due to the formation of carboxypeptidase-
mediated Ang-(1–7). As observed for Ang II, when increasing
concentrations of Ang-(1–7) (10
212–10
26 M) were added to the
invasion assay, parasite invasion was reduced in a dose-dependent
manner with the maximum effect observed at a concentration of
10
28 M, achieving 41% of inhibition (Fig. 5A) 24 h after
treatment. Ang-(1–7) concentrations as low as 10
212 and
10
210 M had a significant inhibitory effect (P,0.005 and
P,0.0001, respectively). When both Ang II and Ang-(1–7) were
assayed concomitantly against the P. falciparum culture, the same
level of inhibition was observed, demonstrating a non-additive
effect of both peptides (Fig. 5B,D). A779 (10
27 M), a specific
antagonist of MAS receptor, known to transduce Ang-(1–7)
signaling, completely reversed the effect of Ang-(1–7). PD123319
(10
27 M) was also able to partially reduce the inhibitory effect of
Ang-(1–7) on the parasite infection. On the other hand, losartan
(10
26 M) did not change the inhibitory effect of Ang-(1–7)
(Fig. 5C). Thus, the effects of angiotensin receptor antagonists
on the inhibitory effect of Ang-(1–7) were similar to those observed
in the presence of Ang II (Figs. 3B and 5C).
Although Ang IV formation is inhibited in infected erythrocytes,
we decided to verify the influence of Ang IV on the parasite
erythrocytic cycle (Fig. 6) because the results could provide
important clues as to why the parasite induces the inhibition of
Ang IV formation. The dose–response relationship between Ang
IV and the parasite erythrocytic cycle showed that the peptide
inhibited infection of new erythrocytes by 70% with the maximum
effect observed at lower doses (10
212 M) (Fig. 6A). Ang II and
Ang-(1–7) achieved the maximum inhibitory effect only at
10
28 M. Ang IV has a more potent inhibitory effect compared
with Ang-(1–7) and Ang II (Fig. 6B) and its effect was not modified
by any of the angiotensin receptor antagonists used: 10
27 M
PD123319, 10
27 M A779 and 10
26 M losartan (Fig. 6C).
Ang-(1–7)-induced inhibition involves MAS-mediated
reduction of erythrocyte PKA activity
It is known that erythrocyte Gs protein is a crucial player during
the malaria blood cycle [8]. Furthermore, it has been shown that
Ang II and Ang-(1–7) can modulate PKA activity in different cell
types [17]. It is well known that erythrocytes display different
kinase activities, including PKA [20]. Thus, we decided to
investigate if erythrocyte PKA could be involved in the effect
of these peptides on the parasite erythrocytic cycle. Because
P. falciparun also expresses PKA (PfPKA) we measured the effect of
Ang II or Ang-(1–7) on erythrocyte PKA activity using the
membrane preparation (Fig. 7). In this way, any influence of
PfPKA is diminished and the investigation is directed to possible
changes in erythrocyte activity. We found that 10
28 M Ang II or
10
28 M Ang-(1–7) inhibited the basal PKA activity and this effect
was reversed by 10
27 M A779 (Fig. 7A). In addition, by evaluating
the number of parasite ring forms, we showed that 10
26 M cAMP
permeable analogue (dibutyryl-cAMP) increased the level of
infection (Fig. 7B). On the other hand, 10
27 M PKA inhibitor
not only reversed the stimulation induced by dibutyryl-AMPc but
also significantly decreased the parasite erythrocytic cycle by 30%
when added alone in the interaction assay (Fig. 7B). 10
212 M
phorbol myristate acetate (PMA), a well-known protein kinase C
(PKC) activator, did not change the level of infection.
Discussion
The invasive stages of the malaria parasite are considered
attractive targets for the development of antimalarial drugs and
vaccines, especially the merozoite invasion of erythrocytes during
the P. falciparum blood stage [9]. Although different invasion
pathways between erythrocytes and Plasmodium sp. have been well
Figure 4. Ang II is promptly metabolized during the invasion
assay. The time course of Ang II metabolism was monitored by mass
spectroscopy (MALDI) in the supernatant of infected (N) and non-
infected (#) erythrocytes incubated with 10
25 M Ang II. (A) Ang II,
(B) Ang-(1–7) and (C) Ang IV levels. The peak areas for different
angiotensin forms (Ang II, Ang-(1–7) and Ang IV) present in the same
spectrum (masses 1046.19, 899.02 and 774.92 Da, respectively) were
obtained and their sum was arbitrarily assigned as 100%. The results are
expressed as means6SE. *Statistically significant compared with the
control value (n=4, P,0.05).
doi:10.1371/journal.pone.0017174.g004
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this process are still poorly understood. Our results provide the
first evidence of the important role of RAS components in
erythrocyte infection by P. falciparum. Here we show that Ang II,
through its carboxypeptidase-mediated metabolic product, Ang-
(1–7), decreases infection of new erythrocytes during development
of the P. falciparum blood stage. This effect of Ang-(1–7) is specific
and probably involves a MAS-mediated PKA inhibition.
The first question that arises from our results is: What is the
source of Ang II involved in the modulation of the erythrocyte
cycle of P. falciparum? Recently, local tissue generation of Ang II
has been described; this peptide could have paracrine or autocrine
effects [21–24]. Therefore, it is possible to postulate that Ang II
produced locally by different tissues such as immune and vascular
cells could modulate the erythrocyte cycle of P. falciparum.
The observation that the effects of Ang II on P. falciparum blood
stage are mediated by Ang-(1–7) reveals a new role for the
(ACE2)/Ang-(1–7)/MAS receptor axis. This idea is strengthened
by the observation that concentrations of Ang-(1–7) that inhibit
parasite invasion (10
212–10
210 M) are compatible with the
physiological serum concentration of Ang-(1–7) [25,26].
It is well known that Ang II promotes endothelial dysfunction
[27], which could be associated with malaria pathogenesis. In this
context, in a study on patients in Orissa/India, Dhangadamajhi
et al. [12] showed that the D allele of ACE I/D polymorphism and
ACE2 CRT substitution, responsible for high level of Ang II in
serum, are associated with mild malaria. The authors postulated
that the protective effect of Ang II could be explained by its
antiplasmodial activity based on the observations of Maciel et al.
[11] in Aedes aegypti infected with Plasmodium gallinaceum. However,
Figure 5. Ang-(1–7) has the same but non-additive effect as Ang II. (A) Dose-response of the effect of Ang-(1–7) on the P. falciparum
erythrocytic cycle. Parasite schizont forms were incubated with a fresh erythrocyte culture at 2% parasitemia in the absence or presence of increasing
concentrations of Ang-(1–7) (10
212–10
26 M). Parasite invasion was determined as the number of intracellular rings after 24 h incubation as described
in the Materials and Methods section (n=8). (B) Parasite schizont forms were incubated with a fresh erythrocyte culture at 2% parasitemia in the
absence or presence of 10
28 M Ang II, 10
28 M Ang-(1–7) or both. Parasite invasion was determined as the number of intracellular rings after 24 h
incubation as described in the Materials and Methods section (n=8). (C) The Ang-(1–7)-mediated effect was avoided by the MAS receptor antagonist.
The effect of Ang II in parasite invasion was determined as described in (B). Where indicated, cultures were pre-treated with 10
26 M losartan, 10
27 M
PD123319 or 10
27 M A779 before addition of Ang-(1–7) (10
28 M). Parasite invasion was determined as the number of intracellular rings after 24 h
incubation as described in the Materials and Methods section (n=6). (D) The effect of Ang II and Ang-(1–7) on the erythrocytic cycle of malaria
parasite obtained from thick blood smears for parasitemia determination by Diff-Quick staining (n=8). The results are expressed as means6SE.
Statistically significant compared with *control and #Ang-(1–7) values (P,0.05). Magnification 6100.
doi:10.1371/journal.pone.0017174.g005
Angiotensin Peptides and Malaria
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host has not yet been determined. In the present study, we showed
that the antiplasmodial effect of Ang II on the P. falciparum
erythrocytic cycle is mediated by its conversion into Ang-(1–7).
An important question regarding the effect of angiotensin peptides
on the P. falciparum erythrocytic cycle is what is the molecular
mechanism involved in this process? The possibility of explaining our
results based on the effect of Ang II on the plasma membrane
structure, as shown by Maciel et al. [11], seems to be ruled out. The
effects of Ang II and Ang-(1–7) on the P. falciparum erythrocytic cycle
were completely abolished by specific receptor antagonists, indicating
a correlation between the structure and function of angiotensin
peptides in the effect observed in the present work.
Here, we clearly show the presence of angiotensin receptors,
AT1,A T 2 and MAS (or AT(1–7)), in erythrocyte membranes, and
their selective blockage by specific antagonists revealed important
clues about their involvement in parasite invasion. The observa-
tion that Ang II and Ang-(1–7) effects are blocked by A779 and
not changed by losartan show the involvement of the MAS
receptor in the modulation of the P. falciparum erythrocytic cycle.
This agrees with the observation that Ang II is metabolized to
Ang-(1–7) in non-infected or even in infected cultures in which
Ang-(1–7) formation is reduced. In addition, the effect of these
peptides was partially abolished by the AT2 receptor antagonist,
PD123319. These results indicate that MAS and AT2 receptors
could be working in a coordinated manner to mediate the effect of
Ang-(1–7). Similar results have been obtained in other systems
such as in the modulation of blood pressure where the effect of
Ang-(1–7) depends on the interaction of both receptors [28,29].
The lack of response of losartan, PD123319 and A779 on Ang IV-
induced inhibition of parasite invasion demonstrates that the
effects of this peptide could be mediated by a specific receptor for
Ang IV (IRAP or AT4) [23].
Angiotensin peptide receptors AT1,A T 2 and MAS belong to
the GPCR family. MAS receptor was recently cloned, but the
signaling pathways activated by this receptor are not well
established [30]. Here we observed that Ang II and Ang-(1–7)
inhibit PKA activity in an A779-sensitive manner similar to
inhibition of the P. falciparum erythrocytic cycle. In agreement with
the role of PKA in the P. falciparum erythrocytic cycle, it was
observed that PKA inhibitor was also able to inhibit the infection,
whereas the permeable analogue of cAMP increases it. This effect
is specific for PKA because the activation of PKC by PMA did not
change the P. falciparum erythrocytic cycle. These results indicate
that the inhibitory effect of Ang-(1–7) on the P. falciparum
erythrocytic cycle is mediated by the inhibition of PKA. P.
falciparum PKA (PfPKA) has been recognized to have an important
role in the development of blood-stage parasites with highest
activity in schizonts [10]. PfPKA modulates anion channel
conductance in erythrocytes, which is important for parasite
growth. However, we measured PKA activity in non-infected
erythrocytes and showed that Ang-(1–7) inhibits the P. falciparum
erythrocytic cycle by modulating erythrocyte PKA activity. In
addition, the a subunit of the Gs protein (Gas) was found in
detergent-resistant rafts of erythrocyte membrane [7]. The Gs
protein-associated signaling mechanisms triggered by two different
GPCR agonists stimulated malaria infection and parasite intra-
cellular maturation in agreement with our results [8].
Figure 6. Ang IV has a greater effect than Ang II and Ang-(1–7).
(A) Dose–response of the effect of Ang IV on the P. falciparum
erythrocytic cycle. Parasite schizont forms were incubated with a fresh
erythrocyte culture at 2% parasitemia in the absence or presence of
increasing concentrations of Ang IV (10
212–10
26 M). Parasite invasion
was determined as thenumberof intracellular rings after24 h incubation
as described in the Materials and Methods section (n=5). (B) Parasite
schizont forms were incubated with a fresh erythrocyte culture at 2%
parasitemiaintheabsence or presenceof 10
28 M Ang II, 10
28 M Ang-(1–
7) or 10
28 M Ang IV. Parasite invasion was determined as the number of
intracellular rings after 24 h incubation as described in the Materials and
Methods section (n=5). (C) The Ang IV-mediated effect was not
prevented by AT1,A T 2 or MAS receptor antagonists. The effect of Ang
IV on parasite invasion was determined as described in (A). Where
indicated, cultures were pre-treated with 10
26 M losartan, 10
27 M
PD123319 or 10
27 M A779 before addition of Ang IV (10
28 M). Parasite
invasion was determined as the number of intracellular rings after 24 h
incubation in thick blood smears as described in the Materials and
Methods section (n=5). The results are expressed as means6SE.
Statistically significant compared with *control value and #Ang II and
Ang-(1–7) (P,0.05).
doi:10.1371/journal.pone.0017174.g006
Angiotensin Peptides and Malaria
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RAS in the P. falciparum blood stage. These results open new
avenues for the development of new antimalarial drugs.
Materials and Methods
Ethics statement
Collection of human blood samples for this study was conducted
according to the protocols approved by the Research Ethics
Committee of the Hospital Universita ´rio Clementino Fraga Filho
from Federal University of Rio de Janeiro (Permit Number 074/10).
All patients provided written informed consent for the collection of
samples and subsequent use. The use of this material follows long-
standing protocols and has not been associated with any adverse or
other unforeseen events and no data of relevance to specific patients
has been generated. Also, this study was carried out in strict accordance
with the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The protocol
was approved by the Institutional Ethics Committee of Federal
University of Rio de Janeiro (Permit Number IBCCF098).
Compounds
N-2-Hydroxyethylpiperazine N-2-ethanesulfonic acid (HEPES),
(tris-hydroxymethyl)-aminomethane (Tris), glucose, sodium bicar-
bonate, hypoxanthine, adenosine triphosphate (ATP, sodium salt),
magnesium chloride, ethylenediaminetetraacetic acid (EDTA),
histone, protein kinase A inhibitor peptide (PKAi), PD123319,
Ang II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe), Ang IV (Val-Tyr-Ile-
His-Pro-Phe) and Ang-(1–7) (Asp-Arg-Val-Tyr-Ile-His-Pro) were
purchased from Sigma Aldrich Co. (St. Louis, MO, USA). Percoll
was purchased from GE Healthcare (Uppsala, Sweden). [
32Pi]Pi
was obtained from the Brazilian Institute of Energetic and Nuclear
Research, Sa ˜o Paulo, Brazil. [c-
32Pi]ATP was synthesized
according to the procedures described by Maia et al. [31]. The
AT1 receptor selective antagonist, losartan, was obtained from
Medley S.A. (Sa ˜o Paulo, Brazil) and A779, the MAS receptor
blocker, was kindly provided by Dr Robson Augusto Souza dos
Santos (Department of Physiology and Biophysics, Institute of
Biological Sciences, Federal University of Minas Gerais, MG,
Brazil). All other reagents were of the highest purity available.
Parasite culture in vitro
Erythrocytic asexual stages of P. falciparum W2 strain, character-
ized as chloroquine resistant and mefloquine sensitive [32], were
maintained in continuous culture in RPMI 1640 medium (Invitro-
gen, CA, USA) in the presence of A-type human blood and 10% A-
positivehumanserum,50 mg/ml gentamicin (Invitrogen,CA,USA)
at 4–5% hematocrit, as described by Trager and Jensen [33]. A
thick blood smear was prepared for parasitemia determination by
Diff-Quick staining and % parasitemiawas described as thenumber
of parasitized red blood cells (PRBC) in 100 erythrocytes, after
analysis of at least five random microscopic fields.
Parasite invasion assay
Parasite mature forms were collected using a Percoll/sorbitol
gradient as described in standard protocols [34]. Briefly, a suspension
of PRBC at 20% hematocrit was centrifuged at 3600 rpm for 30 min
at room temperature in a bench top centrifuge over a 40%, 70% and
90% Percoll/sorbitol gradient. The brown band containing more
than 90% PRBC formed at the 40% and 70% interface was
harvested and used in interaction assays with fresh erythrocyte
cultures at indicated parasitemia levels in the presence or absence of
specific compounds as described in the figure legends. Alternatively,
cultures enriched in the shizont form were obtained after
synchronization with 5% sorbitol as described elsewhere [35].
Mass spectrometry analysis (MALDI)
C18 ZipTip micropipette tips were used for desalting angio-
tensin peptides in the medium. The tips were first activated with
acetonitrile and equilibrated with 0.1% (v/v) trifluoroacetic acid
(TFA) in water. The samples were aspirated and dispensed for
eight cycles and the tips were washed with 0.1% (v/v) TFA in
water three times. The peptides retained on the tips were eluted
using 1.5 ml of a mixture of 50% acetonitrile and 0.1% (v/v) TFA
in water. Then, 0.3 ml of this eluate was immediately spotted on
the ABI 192-target MALDI plate (Applied Biosystems, USA) by
cocrystallization with 0.3 mlo fa na-cyano-4-hydroxycinnamic
acid matrix (10 mg/ml in 30% acetonitrile, 0.3 (v/v) TFA in
Figure 7. Erythrocyte PKA is reduced by Ang II and Ang-(1–7)
and is involved in infection. (A) The membrane fraction of
erythrocytes was assayed for PKA activity as described in the Materials
and Methods section, in the absence or presence of 10
28 MA n gI Io r
10
28 M Ang-(1–7). Where indicated, membranes were pre-treated with
10
26 Mlosartan,10
27 MPD123319or10
27 M A779before the addition of
10
28 M Ang II or 10
28 M Ang-(1–7) (n=6).(B)Parasiteschizont formswere
incubated with a fresh erythrocyte culture at 2% parasitemia in the
absence or presence of 10
27 Md A M P c ,1 0
27 M iPKA or 10
27 M PMA.
Parasite invasion was determined as the number of intracellular rings after
24 h incubation as described in the Materials and Methods section (n=7).
The results are expressed as means6SE. Statistically significant compared
with *control value,
yAng II, ***Ang-(1–7),
#dAMPc (P,0.05).
doi:10.1371/journal.pone.0017174.g007
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Proteomics Analyzer (Applied Biosystems, Foster City, CA). Mass
spectrometry data were acquired in positive and reflectron mode,
mass range 600–1100 Da, using a neodymium-doped yttrium
aluminum garnet (Nd:YAG) laser with a 200-Hz repetition rate.
Typically, 1600 shots were accumulated for spectra. External
calibration was performed using a mixture of four peptides: des-
Arg1-bradykinin (m/z=904.47), angiotensin I (m/z=1296.69),
Glu1-fibrinopeptide B (m/z=1570.68), and adrenocorticotropic
hormone (18–39) (m/z=2465.20). The spectrum files (T2D) were
generated from the raw (or native) mass spectrometry data using
Data Explorer Software v.4.8 (Applied Biosystems). To monitor
angiotensin metabolism, the areas of the peaks for different
angiotensin forms (Ang II, IV and 1–7) present in the same
spectrum, masses 1046.19, 774.92 and 899.02 Da, respectively,
were obtained and their summation was arbitrarily assigned as
100%, making it possible to observe the relative changes of each
form as a function of time.
Erythrocyte membrane preparation and
immunodetection of angiotensin receptors
Erythrocyte membranes were prepared from fresh human A
+
blood, obtained from consenting adult donors, lysed isotonically by
freeze–thaw cycle in liquid nitrogen as described previously [36].
Briefly, blood was filtered in gauze before centrifugation in a Sorvall
centrifuge at 68716g, for 10 min, at 4uC. The pellet was re-
suspended in 20 mM Tris–130 mM KCl buffer (pH 7.4), and cells
were lysed by freezing in liquid nitrogen and thawing naturally at
room temperature. The resulting fluffy pellet was re-suspended and
homogenized in 5 mM Hepes–1 mM EDTA buffer (pH 7.4), and
hemoglobin was washed out by centrifugation at 10,4096g, for
17 min, at 4uC. A second wash was carried out using 5 mM Hepes
buffer (pH 7.4) and then a final wash with a buffer containing
10 mM Tris, 130 mM KCl, 0.5 mM MgCl2 and 50 mM CaCl2.
The clarified preparation was re-suspended in a minimal amount of
the same buffer. The final protein concentration in this enriched
membrane fraction was determined by the Folin phenol method
[37] using bovine serum albumin as a standard.
The membrane preparation was re-suspended and lysed on ice
for 20 min in Ripa buffer (25 mM Tris–HCl, pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1% Triton X-100, 0.5% deoxycholate and
0.1% sodium dodecyl sulfate) freshly supplemented with phospha-
tase and protease inhibitors (10 mM NaF, 5 mM Na3VO4,5m M
Na4P2O7 and 16 protease inhibitor cocktail, Roche, IN, USA).
Aliquots containing 50, 150 or 200 mg protein were re-suspended
in SDS-PAGE loading buffer, resolved on SDS 9% acrylamide
gels and transferred onto Immobilon-P membranes (Millipore,
MA, USA). After blocking with 5% non-fat dry milk/Tris-buffered
saline containing 0.1% Tween 20 for 1 h at room temperature,
membranes were probed overnight, at 4uC, with primary specific
antibodies, followed by horseradish peroxidase-labeled secondary
antibodies (Amersham Biosciences) and visualized with ECLH-plus
reagent (Enhanced Chemiluminescence, Amersham Biosciences).
Rabbit polyclonal anti-human MAS1 was purchased from Abcam
(MA, USA); mouse monoclonal anti-human AT1 and rabbit
polyclonal anti-human AT2 were obtained from Santa Cruz
Biotechnology, Inc. (CA, USA).
Measurement of PKA activity
The PKA activity of isolated erythrocyte membranes was
measured by protein kinase inhibitor-sensitive incorporation of
[
32Pi]Pi from [c-
32P]ATP (7 mCi/mmol), using histone as substrate.
The composition of the reaction medium was 4 mM MgCl2,
20 mM HEPES–Tris (pH 7.0), 1.5 mg/ml histone and 0.7 mg/ml
protein. After 10 min, the reaction was stopped with 40%
trichloroacetic acid (TCA) and the sample was immediately
placed on ice. An aliquot (0.1 ml) was filtered through a Millipore
filter (0.45 mm pore size) and washed with ice-cold 20% TCA
solution and 0.1 M phosphate buffer (pH 7.0). The radioactivity
was quantified using a liquid scintillation counter. The specific
PKA activity was calculated from the difference between the
activity in the absence and in the presence of 10
28 M PKAi [38].
Statistical analysis
Each experiment was performed in independent cell suspen-
sions. The data were analyzed by two-way analysis of variance
(ANOVA), considering the treatments as factors. The significance
of the differences was verified by the Bonferroni t-test. Statistical
analysis was performed using absolute values.
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